BDBM423469 WO2006061714, P39.4::WO2006061714-ID-14::cmdc.202100576, 10e
SMILES: COc1cccc2[nH]c(cc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N(C)C)C=O
InChI Key: InChIKey=SEEIOOYGXIFSRU-YJBOKZPZSA-N
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3C-like proteinase (3CL-PRO) (Human SARS coronavirus (SARS-CoV) (Severe acute re...) | BDBM423469![]() (WO2006061714, P39.4 | WO2006061714-ID-14 | cmdc.20...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The SARS 3CLpro FRET assay measures the protease catalyzed cleavage of TAMRA- SITSAVLQSGFRKMK-(DABCYL)-OH to TAMRA - SITSAVLQ and SGFRKMK- (DABCYL)-O... | WIPO WO2005113580A1 (2005) BindingDB Entry DOI: 10.7270/Q2PV6NRF | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
3C-like proteinase (3CL-PRO) (Human SARS coronavirus (SARS-CoV) (Severe acute re...) | BDBM423469![]() (WO2006061714, P39.4 | WO2006061714-ID-14 | cmdc.20...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | PubMed | n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Experimental Drug Development Centre | Assay Description Please point to the patents. | ChemMedChem (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C3 like protease (SARS coronavirus Urbani) | BDBM423469![]() (WO2006061714, P39.4 | WO2006061714-ID-14 | cmdc.20...) | PDB UniProtKB/TrEMBL GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 5.00E+4 | n/a | 1.80E+7 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description Proteolytic activity of Coronavirus 3C protease is measured using a continuous fluorescence resonance energy transfer assay. The SARS 3CI_pro FRET as... | WIPO WO2006061714A2 (2006) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
3C-like proteinase (3CL-PRO) (Human SARS coronavirus (SARS-CoV) (Severe acute re...) | BDBM423469![]() (WO2006061714, P39.4 | WO2006061714-ID-14 | cmdc.20...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 1.80E+4 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description Protection from SARS Infection: Neutral Red Endpoint The ability of compounds to protect cells against infection by the SARS coronavirus is measured ... | WIPO WO2005113580A1 (2005) BindingDB Entry DOI: 10.7270/Q2PV6NRF | |||||||||||
More data for this Ligand-Target Pair |